Neuregulin 1

You mentioned RAS, the NT-RK, ROS1, MET.

NRG1, RET, STK11, and then you have PD-L1, PD-1.

Are there redundancies or are all of these independent in the patients? And what combinations do you see going forward for treating your patients?

Yeah, no, that's a great question.

But researchers at the University of Manitoba may have found a new breakthrough treatment.

Dr. Soheila Karimi and her team have discovered that restoring a depleted brain protein called NRG1 can repair damaged brain tissue, halt progressive MS, and reverse lost mobility and cognitive function.

It seems NRG1 can be potentially a treatment strategy that can then ameliorate the progressive stage of MS.

Canada has one of the highest MS rates in the world, with Manitoba recording among the highest rates across the country.

We are hoping that we will be able to increase the quality of life of individuals, uh, who are living with MS.

But researchers at the University of Manitoba may have found a new breakthrough treatment.

Dr. Sohaila Karimi and her team have discovered that restoring a depleted brain protein called NRG1 can repair damaged brain tissue, halt progressive MS and reverse lost mobility and cognitive function.

It seems NRG1 can be potentially a treatment strategy that can then ameliorate the progressive stage of MS.

Canada has one of the highest MS rates in the world, with Manitoba recording among the highest rates across the country.

We are hoping that we will be able to increase the quality of life of individuals who are living with MS.

For all non-squamous, and you can consider for squamous, the panel should cover at least 80%.

EGFR, KRAS, ALK, ROS1, BRAF, NTRK, MET Exon 14, RET, HER2 mutations, NRG1 plus HER2 IHC, and CMET HGF receptor IHC along with the PD-L1.

EGFR, ALK, RET, PD-L1 carry Category 1 designations, and that list continues on.

CMET-IHC and HER2-IHC are now part of routine workup because there are drugs tied to these.

So it still holds true that if you find a targetable driver, you go after that first line.

You think about that over chemo and IO.

The only notable exceptions really remain KRAS G12C and NRG1 fusion, where you target agents in the subsequent line setting and you would start with chemo IO first.

And so what are the EGFR need to know and what are the biggest changes?